NKMAX Co., Ltd. Logo

NKMAX Co., Ltd.

Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.

182400 | KO

Overview

Corporate Details

ISIN(s):
KR7182400002
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 돌마로 172 정자동, 헬스케어혁신파크 1층및6층, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NKMAX Co., Ltd. is a biotechnology company specializing in technologies centered on Natural Killer (NK) cells. The company's operations span multiple segments, including the development of NK cell-based immunotherapies for cancer and other diseases. It is a key global manufacturer and supplier of high-quality research reagents, providing recombinant proteins and monoclonal antibodies to over 2,000 research institutions and diagnostic firms worldwide. Additionally, NKMAX offers a precision diagnostic test to quantify NK cell activity for immune function assessment and markets a line of dietary supplements, such as NK365, designed to support the immune system.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-04 00:00
Legal Proceedings Report
회생절차종결결정
Korean 8.5 KB
2025-09-03 00:00
Regulatory News Service
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내 )
Korean 3.2 KB
2025-08-25 00:00
Legal Proceedings Report
회생절차종결신청
Korean 12.4 KB
2025-08-14 00:00
Board/Management Information
대표이사변경
Korean 10.4 KB
2025-08-14 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 13.6 KB
2025-08-13 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 대상결정 기한 안내)
Korean 3.1 KB
2025-08-12 00:00
Audit Report / Information
[기재정정]감사보고서제출 (2024사업연도)
Korean 45.4 KB
2025-08-12 00:00
Audit Report / Information
[기재정정]감사보고서제출 (2023사업연도)
Korean 29.1 KB
2025-08-12 00:00
Regulatory News Service
기타주요경영사항 (자본전액잠식등 사유 해소자료 제출)
Korean 3.6 KB
2025-08-12 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.9 MB
2025-08-12 00:00
Delisting Announcement
기타시장안내 (감사의견 관련 형식적 상장폐지 사유 해소 및 매매거래정지 지속 안내)
Korean 7.0 KB
2025-08-12 00:00
Delisting Announcement
주권매매거래정지기간변경 (상장폐지 사유 해소)
Korean 5.0 KB
2025-08-12 00:00
Audit Report / Information
[기재정정]사업보고서 (2024.12)
Korean 623.6 KB

Automate Your Workflow. Get a real-time feed of all NKMAX Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NKMAX Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NKMAX Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.